Prosthesis Mismatch in TAVR: It’s Real Impact

Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot.

La prudencia es buena consejera para decidir una transfusión en el TAVI

PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2 

Research studies on surgical prosthesis have associated PPM with higher mortality at short, mid and long term. 

There are few studies on post TAVR PPM. Unlike surgical prosthesis, its impact remains to be shown. 

The current study is a meta-analysis of 23 studies with a total 81969 patients. 19612 presented some degree of PPM (23.9%).

Mortality was higher in patients presenting moderate/severe PPM (HR: 1.09 [95% CI: 1.04-1.14]; P < 0.001).

Within the first 30 months, mortality was higher in patients with moderate to severe PPM (HR: 1.1 [95% CI: 1.05-1.16]; P < 0.001). After 30 days, even though mortality was slightly higher, it did not reach statistical significance (HR 0.83 [95% CI: 0.68-1.01]; P = 0.064).

Read also: AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography.

Additionally, PPM moderate and severe were looked at separately, resulting in higher mortality the with more severe PPM, vs. patients with no PPM (HR: 1.25 [95% CI: 1.16-1.36]; P < 0.001). However, this was not the case when looking at moderate PPM (HR: 1.03 [95% CI: 0.96-1.10]; P = 0.398). 

Conclusion

Severe PPM was associated to higher mortality at TAVR followup (unlike moderate PPM). These outcomes call for strategies to prevent severe PPM. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement Meta-Analysis of Kaplan-Meier–Derived Individual Patient Data.

Reference: Michel Pompeu Sá, et al. J Am Coll Cardiol Img 2023;16:298–310.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...